Globally, the prevalence of anti-tuberculosis drug resistance has been increasing. This study sought to identify trends in multidrugresistant tuberculosis (MDR-TB) among foreign-born persons in Alberta, a major immigrant-receiving province of Canada.
At the same time, resistance to one or more of the first-line antituberculosis drugs (isoniazid, rifampin, pyrazinamide and ethambutol) is more common in foreign-born than Canadian-born cases. In 2006, the proportion of culture-positive foreign-born TB cases with resistance to one or more first-line drugs was more than twice that of Canadian-born cases (11% and 5%, respectively). 5 The combination of a high burden of TB and increased drug resistance resulted in 80% of drug-resistant cases in Canada being foreignborn. 5 Moreover, 83-95% of multidrug-resistant (MDR; resistance to at least isoniazid and rifampin) TB cases reported in Canada are foreign-born. [6] [7] [8] Immigrants to Canada from the Western Pacific may be at a higher risk for MDR-TB due to Beijing/W strains of Mycobacterium tuberculosis. 9 Drug resistance and especially MDR-TB are increasing globally, mainly on account of drugs being improperly prescribed (e.g., insufficient number of active agents in the regimen; suboptimal dosage), properly prescribed but unavailable (e.g., interrupted supply; prohibitive patient cost), inadequately supervised (e.g., erratic drug ingestion; omission of one or more active agents), or, more rarely, malabsorbed. [10] [11] [12] Historically, high rates of drug resistance have been observed in countries with high rates of TB and widely available but poorly organized access to health care and medications. 13 Unintentionally, the use of standardized regimens in these low-and middle-income countries in place of individualized regimens based upon drug susceptibility test results may have exacerbated the problem of drug resistance. In a systematic review and meta-analysis of the standardized treatment of previously untreated patients with culture-confirmed pulmonary TB, the cumulative incidence of acquired drug resistance with initially pan-sensitive strains was 0.8% (95% CI 0.5-1.0) compared to 6% (95% CI 4-8) with initially single drug-resistant strains and 14% (95% CI [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] with initially polydrug-resistant strains.
Drug-resistant TB and MDR-TB in particular represent grave threats to TB prevention and control. To treat it, one must use longer, more costly and often more toxic drug regimens. Presumably, low-incidence countries like Canada will not remain isolated from global increases in MDR-TB as emigrants from high MDR-TB burden countries (Table 1 ) may be infected with MDR strains prior to immigration and develop active disease after arrival in Canada. 15 This study sought to identify trends in MDR-TB among foreignborn persons in a major immigrant-receiving province of Canada over the last 30 years.
METHODS
A retrospective cohort study design was used to investigate the prevalence of MDR-TB in foreign-born culture-positive TB cases reported in the province of Alberta between 1982 and 2011. Study cases were identified through the provincial TB Registry and their demographic and clinical features abstracted. Laboratory data were abstracted from the Provincial Laboratory for Public Health, where all mycobacteriology in the province is performed. Demographic data included age at diagnosis, sex, country of birth, and year of arrival. Clinical data included disease type (new active versus relapse/retreatment as defined in the Canadian Tuberculosis Standards), 1 disease site (respiratory versus non-respiratory), and for MDR-TB cases, human immunodeficiency virus (HIV) sero-status. Laboratory data included susceptibilities to isoniazid, rifampin, ethambutol, and streptomycin on all initial isolates dating from 1982 and to pyrazinamide on all initial isolates dating from 1991. From 1982 to 1990, the resistance ratio method was used to determine susceptibilities. 16 Strains with a resistance ratio of ≤2 were considered sensitive, while strains with a ratio of ≥8 were considered resistant. From 1991 to 2010, the BACTEC radiometric system (BACTEC 460TB™, Becton-Dickinson Diagnostic Instrument Systems, Towson, MD), and from 2010 to 2011, the BACTEC nonradiometric system (BACTEC MGIT 960™, Becton, Dickinson and Company, Sparks, MD), were used to determine susceptibilities. All strains found to be resistant by BACTEC 460TB™ or BACTEC MGIT 960™ were retested using the resistance-ratio method to confirm drug resistance.
During the last two decades (1992-2001 and 2002-2011) , all initial isolates of M. tuberculosis in Alberta were DNA fingerprinted using IS6110 restriction fragment length polymorphism, supplemented by spoligotyping in isolates with less than six copies of IS6110 . [17] [18] [19] The DNA fingerprints of MDR-TB isolates were compared to each other and to that of non-MDR-TB isolates.
As informed by the study results and in order to provide insight into the potential feasibility and cost-effectiveness of genotypic drug susceptibility tests for MDR-TB, estimated costs were calculated overall and for groups of foreign-born persons with a high prevalence of MDR-TB based on country of birth. Estimated laboratory costs for the genotypic drug susceptibility tests included consumables, miscellaneous laboratory supplies, laboratory personnel, and overhead costs but excluded the initial purchase of equipment, personnel training, and specimen shipping costs. 20 It was assumed that CAD $1 was equivalent to US $1.
The trends and related observations are summarized below, the two-sided p-values corresponding to the chi-square test or Fisher's exact test using a 5% level of significance. In the analysis, the potential association between calendar year of arrival in Canada (a proxy for calendar year of departure from the country of birth) and MDR-TB was of interest for three reasons: MDR strains of M. tuberculosis are a relatively recent and increasing phenomenon, rifampin therapy having been introduced in 1968; 21 cases result from infections that were acquired prior to immigration; 19 and the genotypic profiles of M. tuberculosis strains among foreign-born persons largely reflect the M. tuberculosis epidemiology of their countries of birth/origin. 22, 23 These factors reasonably suggest that foreign-born persons who more recently departed their countries of birth would have higher rates of MDR-TB than longerstanding residents in Canada.
The reporting of this longitudinal data was approved by the Health Research Ethics Board of the University of Alberta.
RESULTS
Twenty-seven (1.2%) of the 2,234 culture-positive foreign-born TB cases in Alberta in 1982-2011 were MDR-TB cases (Table 2) . Overall, MDR was associated with younger age (<65 years) and TB relapse/retreatment but not sex, country of birth, or disease site (Table 2) .
There was a trend of foreign-born individuals who arrived in more recent calendar years having an increased risk of MDR-TB ( Figure 1 ). In particular, the prevalence of MDR-TB was greatest in the most recent decade of diagnosis (2.11% in 2002-2011) and this was significantly higher than the prevalence in 1992-2001 (0.56%; p=0.009) and 1982-1991 (0.65%; p=0.022) ( Table 3 ). For each decade of diagnosis, the prevalence of MDR-TB increased between 1.5 and 2.3 times when the analysis was limited to cases that arrived in the decade of diagnosis (Table 3) . However, the association between prevalence of MDR-TB and decade of diagnosis was of borderline significance when limited to cases that arrived in the decade of diagnosis (p=0.05).
Twenty-two (81.5%) of the 27 foreign-born MDR-TB cases reported over the three decades were from high MDR-TB burden countries (Table 2) (7 from the Philippines; 4 from China; 4 from Vietnam; 3 from India; 2 from Ethiopia; 1 from Pakistan; and 1 from Nigeria). (Table 3 ). All of the 13 MDR-TB cases that arrived and were diagnosed in the last decade were younger than 65 years at the time of diagnosis.
The prevalence of MDR-TB among cases born in high MDR-TB countries increased from 0.7% in the first two decades (1982-2001) to 2.4% in the last decade (2002-2011) (p=0.008). A similar increase in prevalence was observed among cases born in high MDR-TB burden countries that had arrived in the decade of diagnosis (from 1.4% in the first two decades to 4.6% in the last decade; p=0.016). More specifically, a significant increase in the prevalence of MDR-TB between the first two decades and the last decade was only observed among cases born in the Philippines (from 0% to 4.1%, p=0.017) and Vietnam (from 0.4% to 3.5%, p=0.040). The prevalence of MDR-TB among cases in the last decade from the Philippines and Vietnam increased to 6.5% and 6.3%, respectively, if only TB cases that had arrived in 2002-2011 were considered (Table 3) .
Compared to MDR-TB cases reported in the first two decades (1982) (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) (1993) (1994) (1995) (1996) (1997) (1998) (1999) (2000) (2001) , those reported in the last decade (2002-2011) were more frequently younger than 35 years of age (p=0.265), new active versus relapse/retreatment cases (p=0.102) and diagnosed with nonrespiratory versus respiratory disease (p=0.068) ( Table 4) . None of the MDR-TB cases with known HIV status were co-infected with HIV in either time period. Cases diagnosed in the first two decades were resistant to a mean of 3.1 first-line drugs out of an average of 4.5 drugs tested per case and, in the last decade, a mean of 3.5 firstline drugs out of an average of 5 drugs tested per case.
In 1992-2011, all but one of the MDR-TB isolates had unique DNA fingerprints. The exception was an isolate with an IS6110 lowcopy-number that shared a DNA fingerprint with one non-MDR-TB isolate; a link between these cases could not be established through conventional contact tracing.
In Canada, the optimal cost-effectiveness of genotypic drug susceptibility tests requires that the subset of the foreign-born culturepositive TB cases at greatest risk for MDR-TB be identified 
DISCUSSION
The increased prevalence of MDR-TB among foreign-born TB patients in the past decade, the very high prevalence of MDR-TB among recent emigrants from the Philippines and Vietnam, and the trend towards younger, new active and non-respiratory MDR-TB cases have important implications for TB programming in Alberta and other major immigrant-receiving provinces of Canada (notably Quebec, Ontario and British Columbia). These implications relate to when a foreign-born TB case patient should be suspected of having MDR-TB and the need for a timely diagnosis of MDR-TB. If, prior to the availability of the drug susceptibility test results, a patient with MDR-TB is treated with a standard regimen of isoniazid, rifampin, pyrazinamide and ethambutol, their treatment cannot be expected to succeed. This is because the combination of pyrazinamide and ethambutol, assuming the isolate is susceptible to these drugs, is not a curative regimen. Moreover, our investigation demonstrates that resistance to pyrazinamide and/or ethambutol is not uncommon in MDR-TB isolates (43.5% and 55.6%, respectively, as per Table 4 ) and pyrazinamide is known to be ineffective at preventing resistance to companion drugs. 1, 24 Consequently, administration of the standard regimen to MDR-TB cases that are also resistant to either pyrazinamide or ethambutol is essentially mono-therapy. If administered long enough, this treatment approach will produce resistance to the fourth drug ("amplified" resistance) given the selective advantage that a naturally occurring mutant, resistant to the fourth drug, has in the presence of mono-therapy. 1 Foreign-born persons contribute more than 82% of MDR-TB cases in low TB incidence high-income countries. [6] [7] [8] 25, 26 Despite this commonality, the prevalence of MDR-TB cases among foreign-born individuals in these countries varies markedly due to differences in * One case was culture-positive from both pleural fluid and urine. † Five cases were culture-positive from a cervical lymph node, one from an intra-thoracic lymph node and one from a vertebral body. The case of intrathoracic lymph node TB is grouped here under "non-respiratory" as it had no co-existent respiratory disease and required an invasive procedure for diagnosis. ‡ Only 4 of the 8 MDR-TB cases were tested for susceptibility to pyrazinamide, with 2 (50.0%) of these cases having resistance.
the countries from which the majority of new immigrants arrive (i.e., immigration patterns). For example, the prevalence of MDR-TB in this study (1.4% in 1992-2011 ) was similar to that of the United States (1.7% in 1993-2009). 27 However, foreign-born persons in Alberta had a markedly lower prevalence of MDR-TB than those in Italy (1.6% and 6.2% in 2008-2010, respectively). 25 This difference reasonably relates to Italy receiving a larger proportion of foreignborn persons from higher MDR-TB incidence countries, such as the Ukraine and Moldova, than Canada (data not shown).
The finding that MDR-TB cases in this study had unique DNA fingerprint patterns argues against the likelihood of local transmission that progressed to culture-positive disease. Importantly, local transmission also does not appear to be responsible for the four Canadian-born MDR-TB cases that occurred in the 30-year study period (data not shown). Two of these Canadian-born cases had unique DNA fingerprints on account of being infected with MDR strains while traveling abroad; the other two started with an initially susceptible isolate and became drug-resistant during treatment. 6, 7, 28 The challenge of suspecting and diagnosing MDR-TB in foreignborn TB patients is great given the increasing proportion of younger, new active MDR-TB cases in recent years. These trends, which presumably reflect the ongoing transmission of MDR isolates from MDR source cases to susceptible contacts in their country of origin, 29 dictate that being a new active case (as opposed to a relapse/retreatment case which is well known to carry a risk of drug resistance) 1 does not reliably exclude, or make less likely, the probability of MDR-TB. This contrasts with the usual predictors of MDR-TB, namely: failed treatment with a standard four-drug regimen; previous TB treatment, particularly if it was associated with program or patient non-adherence; treatment of isoniazid-resistant TB in the past; or exposure to a patient who is known to have infectious MDR-TB. 1 The shift toward non-respiratory disease further complicates matters as a diagnosis of MDR-TB cannot be made unless an appropriate specimen is submitted for culture. That is, the provision of an empiric treatment regimen in lieu of specimen collection through an invasive procedure increases the likelihood of a missed diagnosis of MDR-TB.
Genotypic drug susceptibility tests provide an unprecedented opportunity to diagnose MDR-TB prior to the commencement of treatment. 30 These tests, which have >98% sensitivity and specificity for rifampin, 31 target the 81 bp region of the rpoB gene of M. tuberculosis known as the rifampin resistance determining region where 95% of the rifampin-resistant conferring mutations are located. In Canada, the presence of such a mutation strongly suggests the presence of MDR-TB given that only 10% of foreign-born rifampin-resistant TB cases in 2006-2010 had isoniazid-susceptible disease (Custom Report; Canadian Tuberculosis Reporting System, Public Health Agency of Canada, Health Canada). Importantly, however, negative genotypic drug susceptibility test results should not supplant phenotypic drug susceptibility testing in the presence of a high clinical suspicion for MDR-TB. 32 The genotypic drug susceptibility tests that are currently available and recommended by the World Health Organization for the early detection of MDR-TB are i) line probe assays (two commercial kits are currently available: the INNO-LiPA Rif.TB test [Innogenetics NV, Gent, Belgium] and the GenoType MTBDRplus test [Hain Lifescience GmbH, Nehren, Germany]) 33 and ii) the Xpert MTB/RIF test (GeneXpert [Cepheid, Sunnyvale, California, USA]). 34 The GenoTypeMTBDRplus test and the Xpert MTB/RIF test are currently approved for use in Canada. 35 When attempting to identify the high-yield target population for genotypic drug susceptibility tests, both feasibility and costeffectiveness analyses must at least take into account the performance characteristics of the tests 31 as well as the patient's country of birth, year of arrival, age at diagnosis, and possibly disease type (new active versus relapse/retreatment). Even so, in practice, there are only three management options when faced with a possible MDR-TB case: i) delay treatment altogether until phenotypic drug susceptibility test results are available -not an acceptable option if the patient is very ill or highly infectious; ii) within reason, make certain that an empiric regimen is sufficiently surfeit to cover off the possibility of MDR-TB; or iii) use one of the genotypic drug susceptibility tests. Decisions about each of these options are best made by physicians experienced in the management of drug-resistant TB. 
